JP2008511615A - アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質 - Google Patents
アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質 Download PDFInfo
- Publication number
- JP2008511615A JP2008511615A JP2007529372A JP2007529372A JP2008511615A JP 2008511615 A JP2008511615 A JP 2008511615A JP 2007529372 A JP2007529372 A JP 2007529372A JP 2007529372 A JP2007529372 A JP 2007529372A JP 2008511615 A JP2008511615 A JP 2008511615A
- Authority
- JP
- Japan
- Prior art keywords
- enyl
- chloro
- estrogen receptor
- phenyl
- receptor selective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010002261 Androgen deficiency Diseases 0.000 title claims abstract description 30
- 102000015694 estrogen receptors Human genes 0.000 title claims abstract description 23
- 108010038795 estrogen receptors Proteins 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract 4
- 230000002265 prevention Effects 0.000 title claims description 6
- 239000002207 metabolite Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 208000037867 male androgen deficiency Diseases 0.000 claims abstract 3
- 230000006806 disease prevention Effects 0.000 claims abstract 2
- 208000037765 diseases and disorders Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 28
- -1 benzothiophene compound Chemical class 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 20
- 206010058359 Hypogonadism Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- 208000011580 syndromic disease Diseases 0.000 claims description 13
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 12
- 230000001076 estrogenic effect Effects 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 210000003205 muscle Anatomy 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 8
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 8
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 claims description 7
- 206010059594 Secondary hypogonadism Diseases 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 5
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 5
- 230000037182 bone density Effects 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 102000006771 Gonadotropins Human genes 0.000 claims description 4
- 108010086677 Gonadotropins Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical class CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 230000006999 cognitive decline Effects 0.000 claims description 4
- 239000002622 gonadotropin Substances 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- JICOGKJOQXTAIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)-3-methyl-1-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]indol-5-ol Chemical compound C=1C=C(OCCN2CCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 JICOGKJOQXTAIP-UHFFFAOYSA-N 0.000 claims description 3
- JTTIEHQAQHMYJD-QPLCGJKRSA-N 2-[3-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-n,n-dimethylethanamine Chemical compound CN(C)CCOC1=CC=CC(C(=C(\CCCl)C=2C=CC=CC=2)\C=2C=CC=CC=2)=C1 JTTIEHQAQHMYJD-QPLCGJKRSA-N 0.000 claims description 3
- VYYWCVMTGYXAQJ-VHXPQNKSSA-N 2-[3-[(z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol Chemical group OCCOC1=CC=CC(C(=C(\CCCl)C=2C=CC=CC=2)\C=2C=CC=CC=2)=C1 VYYWCVMTGYXAQJ-VHXPQNKSSA-N 0.000 claims description 3
- NKZTZAQIKKGTDB-QPLCGJKRSA-N Fispemifene Chemical compound C1=CC(OCCOCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-QPLCGJKRSA-N 0.000 claims description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 3
- BVVFOLSZMQVDKV-KXQIQQEYSA-N ICI-164384 Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](CCCCCCCCCCC(=O)N(C)CCCC)CC3=CC(O)=CC=C3[C@H]21 BVVFOLSZMQVDKV-KXQIQQEYSA-N 0.000 claims description 3
- 206010024870 Loss of libido Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000031424 hyperprolactinemia Diseases 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 230000020763 muscle atrophy Effects 0.000 claims description 3
- 201000000585 muscular atrophy Diseases 0.000 claims description 3
- 229950002366 nafoxidine Drugs 0.000 claims description 3
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N thianaphthalene Natural products C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 206010007733 Catabolic state Diseases 0.000 claims description 2
- 208000017667 Chronic Disease Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000010428 Muscle Weakness Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 150000001336 alkenes Chemical group 0.000 claims description 2
- 230000008468 bone growth Effects 0.000 claims description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims description 2
- 230000001925 catabolic effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 230000002989 hypothyroidism Effects 0.000 claims description 2
- 208000003532 hypothyroidism Diseases 0.000 claims description 2
- 208000000509 infertility Diseases 0.000 claims description 2
- 230000036512 infertility Effects 0.000 claims description 2
- 231100000535 infertility Toxicity 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 230000035882 stress Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000000383 tetramethylene group Chemical class [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 2
- XZYDRUBEVFWAQF-WCWDXBQESA-N 3-[(e)-4-chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=C(O)C=CC=1)=C(\CCCl)C1=CC=CC=C1 XZYDRUBEVFWAQF-WCWDXBQESA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 208000006132 lipodystrophy Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 208000037921 secondary disease Diseases 0.000 claims 1
- 210000003699 striated muscle Anatomy 0.000 claims 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 112
- 229960003604 testosterone Drugs 0.000 description 56
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 37
- 210000002966 serum Anatomy 0.000 description 17
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000328 estrogen antagonist Substances 0.000 description 7
- 239000003098 androgen Substances 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 102000009151 Luteinizing Hormone Human genes 0.000 description 5
- 108010073521 Luteinizing Hormone Proteins 0.000 description 5
- 206010052649 Primary hypogonadism Diseases 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010067572 Oestrogenic effect Diseases 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 208000011622 Testicular disease Diseases 0.000 description 4
- 229940046836 anti-estrogen Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229940028334 follicle stimulating hormone Drugs 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940040129 luteinizing hormone Drugs 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000002381 testicular Effects 0.000 description 4
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 201000000079 gynecomastia Diseases 0.000 description 3
- 229960005026 toremifene Drugs 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010021067 Hypopituitarism Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 201000005746 Pituitary adenoma Diseases 0.000 description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 2
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 2
- 238000009165 androgen replacement therapy Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229950004203 droloxifene Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 201000002733 hypogonadotropic hypogonadism 23 with or without anosmia Diseases 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 229940124598 therapeutic candidate Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- XENFGWFELBTJTG-CYYJNZCTSA-N 3-[(e)-4-chloro-1-[4-(2-imidazol-1-ylethoxy)phenyl]-2-phenylbut-1-enyl]phenol Chemical compound OC1=CC=CC(C(=C(/CCCl)C=2C=CC=CC=2)\C=2C=CC(OCCN3C=NC=C3)=CC=2)=C1 XENFGWFELBTJTG-CYYJNZCTSA-N 0.000 description 1
- XENFGWFELBTJTG-RQZHXJHFSA-N 3-[(z)-4-chloro-1-[4-(2-imidazol-1-ylethoxy)phenyl]-2-phenylbut-1-enyl]phenol Chemical compound OC1=CC=CC(C(=C(\CCCl)C=2C=CC=CC=2)\C=2C=CC(OCCN3C=NC=C3)=CC=2)=C1 XENFGWFELBTJTG-RQZHXJHFSA-N 0.000 description 1
- 208000026817 47,XYY syndrome Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000028482 Hypothalamic disease Diseases 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010066833 Sertoli cell-only syndrome Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010056894 XYY syndrome Diseases 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 description 1
- 229950005529 arzoxifene Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000011272 imaginal disc-derived genitalia development Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000011474 orchiectomy Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 230000006584 pituitary dysfunction Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 208000017402 pituitary gland disease Diseases 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001836 utereotrophic effect Effects 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60690704P | 2004-09-03 | 2004-09-03 | |
| FI20041216A FI20041216A0 (fi) | 2004-09-21 | 2004-09-21 | Menetelmä androgeenivajeen hoitoon tai estoon |
| PCT/FI2005/000333 WO2006024689A1 (en) | 2004-09-03 | 2005-07-20 | Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008511615A true JP2008511615A (ja) | 2008-04-17 |
Family
ID=35999733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007529372A Abandoned JP2008511615A (ja) | 2004-09-03 | 2005-07-20 | アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1786408A4 (es) |
| JP (1) | JP2008511615A (es) |
| KR (1) | KR20070059110A (es) |
| AU (1) | AU2005279178A1 (es) |
| BR (1) | BRPI0514701A (es) |
| CA (1) | CA2578852A1 (es) |
| MX (1) | MX2007002606A (es) |
| NO (1) | NO20071160L (es) |
| RU (1) | RU2007112114A (es) |
| WO (1) | WO2006024689A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507975A (ja) * | 2014-03-10 | 2017-03-23 | アンドルシェルシュ・インコーポレイテッド | 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5363344B2 (ja) | 2007-02-14 | 2013-12-11 | ホルモス メディカル リミテッド | 治療に有用なトリフェニルブテン誘導体の調製方法 |
| WO2008157335A2 (en) * | 2007-06-13 | 2008-12-24 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
| ES2627692T3 (es) | 2010-06-10 | 2017-07-31 | Aragon Pharmaceuticals, Inc. | Moduladores de receptores de estrógenos y usos de los mismos |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US9975832B2 (en) | 2014-12-29 | 2018-05-22 | Olon S.P.A. | Process for the preparation of ospemifene and fispemifene |
| WO2023175010A1 (fr) * | 2022-03-15 | 2023-09-21 | Centre D'etude Des Cellules Souches (Cecs) | Utilisation du bazedoxifene pour augmenter la survie musculaire |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
| US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| CO5271697A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
| JP2003534375A (ja) * | 2000-05-26 | 2003-11-18 | フィッチ，ハリー | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 |
| US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| ES2319785T3 (es) * | 2001-11-29 | 2009-05-12 | Gtx, Inc. | Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos. |
-
2005
- 2005-07-20 KR KR1020077006922A patent/KR20070059110A/ko not_active Application Discontinuation
- 2005-07-20 RU RU2007112114/15A patent/RU2007112114A/ru not_active Application Discontinuation
- 2005-07-20 AU AU2005279178A patent/AU2005279178A1/en not_active Abandoned
- 2005-07-20 BR BRPI0514701-8A patent/BRPI0514701A/pt not_active IP Right Cessation
- 2005-07-20 JP JP2007529372A patent/JP2008511615A/ja not_active Abandoned
- 2005-07-20 WO PCT/FI2005/000333 patent/WO2006024689A1/en active Application Filing
- 2005-07-20 EP EP05771627A patent/EP1786408A4/en not_active Withdrawn
- 2005-07-20 CA CA002578852A patent/CA2578852A1/en not_active Abandoned
- 2005-07-20 MX MX2007002606A patent/MX2007002606A/es unknown
-
2007
- 2007-03-01 NO NO20071160A patent/NO20071160L/no not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507975A (ja) * | 2014-03-10 | 2017-03-23 | アンドルシェルシュ・インコーポレイテッド | 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療 |
| JP2018165269A (ja) * | 2014-03-10 | 2018-10-25 | アンドルシェルシュ・インコーポレイテッド | 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療 |
| JP2020176149A (ja) * | 2014-03-10 | 2020-10-29 | アンドルシェルシュ・インコーポレイテッド | 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療 |
| JP7080117B2 (ja) | 2014-03-10 | 2022-06-03 | アンドルシェルシュ・インコーポレイテッド | 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療 |
| JP2022183311A (ja) * | 2014-03-10 | 2022-12-08 | アンドルシェルシュ・インコーポレイテッド | 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007002606A (es) | 2007-05-15 |
| AU2005279178A1 (en) | 2006-03-09 |
| EP1786408A4 (en) | 2010-07-28 |
| EP1786408A1 (en) | 2007-05-23 |
| NO20071160L (no) | 2007-05-25 |
| BRPI0514701A (pt) | 2008-06-24 |
| CA2578852A1 (en) | 2006-03-09 |
| WO2006024689A1 (en) | 2006-03-09 |
| KR20070059110A (ko) | 2007-06-11 |
| RU2007112114A (ru) | 2008-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108135177B (zh) | 用于治疗癌症的方法 | |
| TWI339118B (en) | Treating muscle wasting with selective androgen receptor modulators | |
| AU2013225869B2 (en) | Combination therapy for treating androgen deficiency | |
| DE602004002591T9 (de) | Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen | |
| JP2008511615A (ja) | アンドロゲン欠乏症の治療法または予防法に使用する医薬調製物の製造に用いるエストロゲン受容体選択的調節物質 | |
| US20060293294A1 (en) | Method for treatment or prevention of androgen deficiency | |
| JP2015508825A5 (es) | ||
| JPH09315962A (ja) | テストステロンを増加させる方法 | |
| ZA200400142B (en) | Methods and materials for the treatment of testos terone dificiency in men. | |
| UA113291C2 (xx) | Метаболіти транскломіфену і їх застосування | |
| TWI458478B (zh) | 用於代謝症候群與第２型糖尿病的反式氯米芬 | |
| JP6743001B2 (ja) | シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療 | |
| MX2007000741A (es) | Composiciones que comprenden inhibidores de la 5-alfa-reductasa y moduladores de receptores de estrogeno selectivos (serms) y metodos de uso de los mismos. | |
| KR20030001535A (ko) | 항안드로겐 효과 및 항에스트로겐 효과를 제공하기 위한비칼루타미드 및 타목시펜의 약학 조합물 | |
| JP2015506988A (ja) | 半減期の短い選択的エストロゲン受容体モジュレーターおよびその使用 | |
| CN1893955A (zh) | 用于预防和治疗激素依赖性疾病的包含孕酮受体拮抗剂和纯抗雌激素的组合物 | |
| TW200526201A (en) | Treating bone-related disorders with selective androgen receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080523 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20091228 |